AIM Historical Financial Ratios
| AIM Stock | USD 0.23 0.02 8.00% |
AIM ImmunoTech is presently reporting on over 81 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.28 or Days Sales Outstanding of 2 K will help investors to properly organize and evaluate AIM ImmunoTech financial condition quickly.
AIM |
About AIM Financial Ratios Analysis
AIM ImmunoTechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate AIM ImmunoTech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on AIM financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across AIM ImmunoTech history.
AIM ImmunoTech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing AIM ImmunoTech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on AIM ImmunoTech sales, a figure that is much harder to manipulate than other AIM ImmunoTech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from AIM ImmunoTech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.At this time, AIM ImmunoTech's Income Quality is very stable compared to the past year. As of the 8th of January 2025, Debt To Equity is likely to grow to 0.37, while PTB Ratio is likely to drop 2.28.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 4.3K | 2.1K | 1.9K | 2.0K | PTB Ratio | 0.39 | 2.09 | 2.4 | 2.28 |
AIM ImmunoTech fundamentals Correlations
Click cells to compare fundamentals
AIM ImmunoTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AIM ImmunoTech fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 349.68 | 322.61 | 106.28 | 105.81 | 95.22 | 90.46 | |
| Days Sales Outstanding | 2.5K | 4.4K | 4.3K | 2.1K | 1.9K | 2.0K | |
| Book Value Per Share | 1.92 | 1.2 | 0.8 | 0.21 | 0.24 | 0.23 | |
| Free Cash Flow Yield | (0.19) | (0.34) | (1.09) | (1.02) | (1.18) | (1.12) | |
| Operating Cash Flow Per Share | (0.33) | (0.29) | (0.34) | (0.44) | (0.39) | (0.41) | |
| Stock Based Compensation To Revenue | 6.36 | 11.61 | 6.77 | 1.2 | 1.08 | 1.03 | |
| Capex To Depreciation | 0.81 | 0.82 | 1.06 | 2.46 | 2.21 | 2.32 | |
| Ev To Sales | 127.5 | 85.99 | (79.65) | 82.43 | 94.8 | 90.06 | |
| Free Cash Flow Per Share | (2.59) | (0.34) | (0.31) | (0.45) | (0.4) | (0.43) | |
| Roic | (0.28) | (0.37) | (0.56) | (3.12) | (3.59) | (3.41) | |
| Net Income Per Share | (0.51) | (0.45) | (0.44) | (0.6) | (0.54) | (0.56) | |
| Payables Turnover | 2.1 | 4.29 | 52.85 | 0.006519 | 0.005867 | 0.005573 | |
| Sales General And Administrative To Revenue | 53.09 | 64.24 | 92.72 | 104.64 | 94.17 | 98.88 | |
| Research And Ddevelopement To Revenue | 35.09 | 56.83 | 49.57 | 54.15 | 48.74 | 51.18 | |
| Capex To Revenue | 2.61 | 3.65 | 4.69 | 1.92 | 2.9 | 3.18 | |
| Cash Per Share | 1.22 | 1.02 | 0.71 | 0.27 | 0.31 | 0.29 | |
| Pocfratio | (5.5) | (3.12) | (0.93) | (1.0) | (0.9) | (0.95) | |
| Interest Coverage | (22.9) | (29.14) | (22.55) | (281.16) | (253.05) | (265.7) | |
| Capex To Operating Cash Flow | (0.0574) | (0.0453) | (0.0168) | (0.0275) | (0.0248) | (0.026) | |
| Pfcf Ratio | (5.2) | (2.98) | (0.91) | (0.98) | (0.88) | (0.92) | |
| Days Payables Outstanding | 173.44 | 85.02 | 6.91 | 56.0K | 50.4K | 52.9K | |
| Income Quality | 0.95 | 0.72 | 0.73 | 0.83 | 0.66 | 0.67 | |
| Roe | (0.84) | (0.27) | (0.38) | (2.83) | (3.25) | (3.09) | |
| Ev To Operating Cash Flow | (2.0) | (0.83) | 0.7 | (0.78) | (0.7) | (0.74) | |
| Pe Ratio | (3.51) | (2.02) | (0.71) | (0.74) | (0.66) | (0.7) | |
| Return On Tangible Assets | (0.26) | (0.39) | (0.55) | (1.7) | (1.53) | (1.45) | |
| Ev To Free Cash Flow | (1.9) | (0.8) | 0.69 | (0.76) | (0.69) | (0.72) | |
| Earnings Yield | (0.29) | (0.49) | (1.41) | (1.36) | (1.56) | (1.48) | |
| Intangibles To Total Assets | 0.0232 | 0.0342 | 0.0479 | 0.12 | 0.14 | 0.0707 | |
| Net Debt To E B I T D A | (0.6) | 2.78 | 1.75 | 1.32 | 0.17 | 0.16 | |
| Current Ratio | 36.58 | 74.61 | 26.69 | 1.68 | 1.51 | 1.44 | |
| Tangible Book Value Per Share | 1.88 | 1.16 | 0.76 | 0.16 | 0.19 | 0.18 | |
| Receivables Turnover | 0.17 | 0.15 | 0.0823 | 0.0841 | 0.2 | 0.19 | |
| Graham Number | 4.7 | 3.51 | 2.81 | 1.68 | 1.93 | 1.84 | |
| Shareholders Equity Per Share | 1.92 | 1.2 | 0.8 | 0.21 | 0.24 | 0.23 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share | Quarterly Revenue Growth 0.19 | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.